Advertisement

Topics

PARP Inhibitors Effective but Costly for Recurrent Ovarian Cancer

08:18 EDT 29 Jun 2017 | Cancer Networks

Niraparib is the most effective but most costly of the currently FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.

Original Article: PARP Inhibitors Effective but Costly for Recurrent Ovarian Cancer

NEXT ARTICLE

More From BioPortfolio on "PARP Inhibitors Effective but Costly for Recurrent Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...